Chart-Typ:
Zeitraum:
| Johnson & Johnson's DARZALEX FASPRO Improves Myeloma Survival And MRD Response Rates | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) shared new findings at the 2025 ASCO Annual Meeting from two Phase 3 studies, PERSEUS and CEPHEUS, highlighting the long-term benefits of a... ► Artikel lesen |
| Johnson & Johnson Says Carvykti Achieved Treatment-free Remissions For 5 Years In Myeloma Patients | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced Tuesday new long-term follow-up data from the Phase 1b/2 Cartitude-1 study demonstrating 33 percent of patients in the study with... ► Artikel lesen |
| Johnson & Johnson's Trispecific Antibody Show Promising Response In Myeloma Patients | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced Tuesday initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed... ► Artikel lesen |
| DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | Anzeige / WerbungAm gestrigen Feiertag in Deutschland rutschte der DAX noch einmal deutlich ab und markierte erst unter 24.000 Punkten seinen Boden. Dem war ein neues Allzeithoch vorausgegangen. In... ► Artikel lesen |
| Biogen Partners City Therapeutics To Develop Select Novel RNAi Therapies | WESTON (dpa-AFX) - Biogen Inc. (BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company, announced Tuesday a strategic collaboration to develop select novel RNAi therapies.Through... ► Artikel lesen |
| Biogen Inc.: Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies | Collaboration leverages City Therapeutics' next-generation RNAi engineering technologies and Biogen's extensive drug development expertiseCAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc.... ► Artikel lesen |
| Ionis Pharmaceuticals, Inc.: Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. | - Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world - - Ionis will continue to independently commercialize TRYNGOLZA (olezarsen)... ► Artikel lesen |
| Ionis Pharma Reports Approval Of WAINZUA In The EU | LONDON (dpa-AFX) - Ionis Pharmaceuticals (IONS) announced that Ionis and AstraZeneca's WAINZUA has been approved in the European Union for the treatment of hereditary transthyretin-mediated... ► Artikel lesen |
| Ionis Pharmaceuticals, Inc.: WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy | - Second major approval for WAINZUA, which is marketed in the U.S. as WAINUA - - EU approval based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BG MEDICINE INC finden Sie auf Wallstreet Online.